What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs
ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down with Jen Can NuSH (@jcanNuSH) to break down the molecules...
16 Juni 1h 15min
Retatrutide Before FDA Approval? Lilly Just Changed the Conversation
Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.
9 Juni 20min
Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs
Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...
2 Juni 20min
Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War
https://linktr.ee/manonthemounjaro
26 Maj 30min
Lilly Bets $8B on Weight Loss Future
https://linktr.ee/manonthemounjaro
19 Maj 23min
The Next Two Weeks in GLP1 Are Huge, Here's Why
http://www.otplinks.com
12 Maj 1h 7min
He Took Retatrutide 40mg and Proved a Point
This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...
5 Maj 36min
